New Drugs from Marine Organisms in Alzheimer’s Disease

Patrizia Russo 1,*, Aliaksei Kisialiou 1, Palma Lamonaca 1, Rossana Moroni 1, Giulia Prinzi 1 and Massimo Fini 2

Received: 5 November 2015; Accepted: 21 December 2015; Published: 25 December 2015

Academic Editor: George Perry

1 Clinical and Molecular Epidemiology Division, IRCCS “San Raffaele Pisana” Via di Valcannuta, 247, Romel-00166, Italy; aliaksei.kisialiou@sanraffaele.it (A.K.); palma.lamonaca@gmail.com (P.L.); rossana.moroni@sanraffaele.it (R.M.); giulia.prinzi@sanraffaele.it (G.P.)

2 Scientific Direction, IRCCS “San Raffaele Pisana” Via di Valcannuta, 247, Rome I-00166, Italy; massimo.fini@sanraffaele.it

* Correspondence: patrizia_russo@hotmail.it or patrizia.russo@sanraffaele.it; Tel.: +3906522533769

Abstract: Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Current approved drugs may only ameliorate symptoms in a restricted number of patients and for a restricted period of time. Currently, there is a translational research challenge into identifying the new effective drugs and their respective new therapeutic targets in AD and other neurodegenerative disorders. In this review, selected examples of marine-derived compounds in neurodegeneration, specifically in AD field are reported. The emphasis has been done on compounds and their possible relevant biological activities. The proposed drug development paradigm and current hypotheses should be accurately investigated in the future of AD therapy directions although taking into account successful examples of such approach represented by Cytarabine, Trabectedin, Eribulin and Ziconotide. We review a complexity of the translational research for such a development of new therapies for AD. Bryostatin is a prominent candidate for the therapy of AD and other types of dementia in humans.

Keywords: marine drugs; Alzheimer’s disease; mechanisms of activity; clinical/preclinical studies; bryostatin; new drugs

1. Introduction

Right now, 46.8 million persons in the world are suffering from dementia and it is expected that this number will increase to 74.7 million in 2030 and 131.5 million in 2050 [1]. Alzheimer’s disease (AD) is the main cause of dementia in the elderly [2]. AD is a progressive, continuous and incurable brain disorder leading to increase severe disability such as memory loss (amnesia), minimal to no communication (aphasia), the inability to perform activities of daily living (ADL) (apraxia), the impairment of the sensory input (development of agnosias). In briefly, AD is a multifactorial neurodegenerative disorder that affects cognition (memory, thinking, and language abilities), quality of life and self-sufficiency in elderly [2]. AD is strictly related to aging, indeed the majority of cases (≥ 90%) are initially diagnosed among persons ≥ 65 years of age (AD with late onset—LOAD) [1]. Two percent to ten percent of cases diagnosed before the age of 65 years (AD with early onset—EOAD). Adominant EOAD caused by several genetic mutations [3]. In particular, genes involved in the production of the amyloid β (Aβ) peptides such as amyloid precursor protein (APP), Presenilin 1 (PSEN1), and 2 (PSEN2) may account for as much as 5%-10% of the EOAD incidence [3]. The allele ε4 of Apolipoprotein E (APOE) is considered an established genetic risk factor for both EOAD and LOAD [3,4]. APOEε4 homozygous carriers show eightfold elevation of risk of AD...
compared to the general population. However, up to 75% of APOEε4 heterogeneous subjects do not progress to AD during their lifetime, and on the other hand, up to 50% of AD patients aren’t APOEε4 carriers [3,4]. APOE is involved in lipid transport as well as in Aβ peptides transport [4].

At least 21 novel genetic risk loci has been emerged from recently performed genome-wide association studies (GWAS) of AD and massive parallel resequencing [3]. At the pathological level intracellular neurofibrillary tangles (NT: microtubule–associated protein tau (τ)) and extracellular amyloid plaques characterize AD brains [5]. Additionally, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacular degeneration, and neuron loss are observed in AD post-mortem brain samples [5]. AD is an extensive neurodegenerative disease starting from the entorhinal cortex (limbic regions). Moreover, a post-mortem AD brain tissue autopsy reveals an impressive shrinkage in almost all neocortical areas, as well as a loss of subcortical structures such as the substantianigra, are largely spared. The molecular mechanisms that trigger sporadic LOAD, for the most part, are unknown. AD is a multifactorial disorder with a great number of leading mechanisms that support the postulation of different molecular etiological hypotheses [6–18].

The most well-supported scientific hypotheses are:

(i) “The amyloid cascade hypothesis”. For decades the hypothesis was the main “framework” for AD research. The pathological accumulation of Aβ, as amyloid plaques, frequently observed in AD brains [6], was considered the main etiopathology cause. The increased Aβ accumulation, according to this hypothesis, triggers a cascade of events leading to synaptic dysfunction, memory loss and structural brain damage in AD advanced stages. The hypothesis that Aβ peptides are the causal factors of AD is now considered an oversimplification. Consequently, a linear toxicity model (increased Aβ deposition which in turn increases a brain damage) is incorrect. However, the possible Aβ role is to trigger other downstream events, such as τ aggregation. The failure of Aβ-targeted clinical trials in AD patients supports the hypothesis that Aβ peptides may be recurrent contributors in the AD process, but it is neither necessary, nor sufficient [6];

(ii) “The cholinergic hypothesis”. The hypothesis is based on the observation of significant loss in cholinergic signaling such as a severe loss of brain white matter with the reduction of cholinergic neurons of the basal forebrain (i.e., Acetylcholine (ACh), nicotine/muscarinic binding sites (nicotinic/muscarinic receptor: nAChR, mAChR)) observed in post-mortem cerebral cortex of AD patients [7]. A significant reduction of the number of nicotine and ACh binding sites in cerebral cortex of AD patients supports a decrease in the number of both nAChR and mAChR. Moreover, the activity of choline acetyltransferase (ChAT) and acetylcholinesterase (AChE) is decreased. The two enzymes are involved in ACh synthesis/degradation: ChAT transfers an acetyl group from the coenzyme (acetyl-CoA) to choline yielding ACh while AChE catalyzes ACh breakdown. Consequently, any failure in the cholinergic system is strictly linked to attention, learning and memory deficit;

(iii) “The glutamatergic hypothesis”. The hypothesis is based on the gradual deterioration of proper synaptic functioning through GluN2A-containing N-methyl-D-aspartate receptors (NMDARs) and the development of excitotoxicity through GluN2B-containing NMDARs. Alteration in NMDARs activity may involve Aβ-induced synaptic impairment, spine loss and neurodegeneration [8];

(iv) “The mitochondrial hypothesis” [9]. The hypothesis predicts that mitochondrial dysfunctions trigger energy metabolism impairment, with excessive reactive oxygen species (ROS) formation and consequent DNA damage [10];

(v) “The metabolic hypothesis” is based on the assumption that mitochondrial dysregulation up-regulates the oxidative phosphorylation (OXPHOS) activity (known as “inverse Warburg effect”) [11];
(vi) “The τ hypothesis”. The hypothesis is based on the observation that τ dysfunction (abnormal levels, hyperphosphorylation, or ubiquination), in the absence of amyloid pathology, is sufficient to cause synaptic and neuronal loss [12];

(vii) “The memory kinase hypothesis” is based on the involvement of Protein Kinase C (PKC) in acquisition and modification of dendritic spines, in neurite retraction and in synaptic Plasticity [13] (For details see Bryostatin-1 section);

(viii) “The neuro-inflammation hypothesis”. The hypothesis implies an innate immune response characterized by the release of inflammatory mediators [14,15];

(ix) “The clearance systems hypothesis” is based on Aβ clearance failure. In briefly, an excess deposition of Aβ peptides results from an imbalance between their production and clearance; in both EOAD and LOAD, as well as at the prodromal stage [16];

(x) “The Cognitive Reserve (CR) hypothesis”. The hypothesis is proposed to explain the gap between the brain insult and the pathological manifestations. The CR includes two elements: brain (i.e., brain size, synaptic count, and dendritic branching) and cognitive (i.e., neural and compensation reserve) reserve. Two components of the reserve work together and protect the brain from AD [17].

(xi) “The disconnection hypothesis”. The hypothesis is based on the disrupted functional connectivity in AD brains association area [18–20].

Probably, the above mechanisms may work altogether through interactions between genetic, molecular and cellular events [21]. For example, the α7-nAChR may be a convergent point for several hypotheses. Aβ binds to α7-nAChR with a high affinity. Aβ induces τ phosphorylation through α7-nAChR activation. Aβ concentrations, Aβ aggregation conditions, as well as possible presence of β2 nicotinic subtype in the composition of the heteromer α7β2-nAChR, may cause activation or inhibition of α7-nAChR with consequent neuroprotection or neurotoxicity effect [22,23]. α7-nAChR activation of macrophage, microglia and neuron induces the JAK2/STAT3 anti-inflammation pathway [23]. Moreover, soluble oligomeric Aβ peptides engage α7-nAChR in astrocytes, in which glutamate release, in turn, activates neuronal NMDARs and consequent synaptic damage [24].

There are only four currently FDA/EMA-approved drugs. Two drugs namely: donepezil, rivastigmine (ATC codes N06DA02, N06DA03, respectively) are based on the cholinergic and/or glutamatergic hypotheses. These drugs (reversible acetylcholinesterase inhibitors (AChEIs)) act through inhibition of AChE and butyrylcholinesterase (BChE). Galantamine (ATC code N06DA04) is a competitive, reversible α7-nAChR allosteric inhibitor [22]. Memantine (ATC code N06DX02) is NMDARs antagonist [25]. AChEIs inhibit AChE by breaking down ACh, thus, increasing ACh effects, which, hypothetically, elevate cholinergic signaling in neurons and limit inflammation [15,25].

No drugs has been proved to be effective in the treatment of Mild Cognitive Impairment (MCI, a prodromal state of AD). Consequently, AChEIs and memantine were not approved by FDA/EMA for MCI subjects [26]. None of these drugs change or block disease progression; they may only ameliorate symptoms in a restricted number of patients and for a restricted period of time [25,27]. Tacrine (ATC code N06DA01) is a reversible AChEI, currently discontinued because of liver toxicity, was the first drug receiving FDA approval in 1993 [28], donepezil—in 1996. Consequently, memantinereceived FDA approval in 2003, galantamine—in 2004 and, finally, rivastigmine—in 2006. In the last 22 years only five AD drugs were FDA-approved, in comparison to 29 new anticancer agents approvedin 2013–2015 [29]. It is obvious that there is a pressing need to new AD/MCI drugs. Thus, in 2015 WHO includes among health research priorities: “Implement and take the necessary steps towards the ambition to identify a cure or a disease-modifying therapy for dementia by 2025 as adopted by the G8 Summit in December 2013” [30].
2. Drugs from Marine Organisms

Marine organisms live in different underwater habitats (environment) characterized by specific chemical and physical properties such as water salt concentrations, pressure, temperature (including extreme), light penetration, oxygen concentrations and radiation exposure, and ocean currents. The distinctive marine environment dictates the marine organism’s adaptation involving their structural (or morphological), physiological and behavioral adaptations [31,32]. Marine organisms are comprised in six different kingdoms: Bacteria, Protozoans, Chromists (including Seaweeds), Fungi, Plants, although few types flourish in the marine environment, and Animals including jellyfish, sponges, sea spiders, bryozoans, mussels, sea stars, fish and whales. Marine organisms or marine organisms with associated microbial communities can synthesize extremely structural different metabolites used to immobilize and capture prey and to defend against predators. These compounds range from small peptides (i.e., conopeptides of 7–27 amino acids in length) and enzymes to more complex secondary metabolites (i.e., ecteinascidin, a tetrahydroisoquinoline alkaloid), which show significant bioactivities that efficiently disturb vital physiological systems, in particular, those linked to movement, respiration and circulation. These molecules enclose the potential to become a lead in AD innovative drug discovery [32–39]. In this field of research a breakthrough discovery is represented by the FDA/EMA-approved drugs: Cytarabine (from Cryptotethyacrypta), Trabectedin (from Ecteinascidia turbinate) and Eribulinmesylate (from Halichodriaokadai) discovered and developed as anticancer agents, and Ziconotide (from Conus magus) approved for treatment of neuropathic pain [33–39].

In this review, selected examples were reported in order to exemplify the development of marine-derived compounds for neurodegenerative diseases, specifically, for AD. The emphasis was done on new compounds with their relevant biological activities. Accordingly, new compounds without biological activity or, at least, not tested in cells were therefore not included.

2.1. Bryostatin-1

The pharmacology of Bryostatin-1 (Bry-1, C_{47}H_{68}O_{17} M.W. = 905.04, Figure 1) is emblematic [40,41] of marine drugs potential, since Bry-1 is exploited in non-correlated different diseases such as cancer, HIV and neurodegenerative diseases. Bry-1 was initially isolated from the extract of Bugulaneritina (or brown bryozoans, natively distributed in tropical and subtropical waters, now widespread globally through vessels hulls attachment to the ships) at the end of the 60s by George Pettit [42]. Bry-1 is a macrolide lactone characterized by 11 chiral centers. Currently, Bry-1 is obtained in total synthesis [43,44]. Cancer is the largest area of pharmacological exploitation of Bry-1 and its derivatives including apoptotic restoration, multidrug-resistance circumvention, immune system stimulation, and drugs synergism. Although as a single agent Bry-1’s activity was disappointing. Promising results were obtained in phase II clinical trials when Bry-1 was administered in combinations with cytotoxic agents such as, for example, Bry-1 and Cisplatin for the treatment of metastatic or unresectable stomach cancer [45].

Among the new rising important pharmacological activities of Bry-1 there is the ability to reactivate latent viral infection [46], also in human astrocytes, through the PKC/NF-κB-dependent mechanism [47]. The goal of the ongoing interventional randomized double blind dose-finding trial is to evaluate two different doses of Bry-1 on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral treatment [48].

Bry-1 is a potent modulator of PKC [49]. PKC comprises eight isoforms (conventional: α, βI/βII, γ; and novel: δ, ε, η, θ) enclosing the regulatory C1 domains [49]. The rings of Bry-1 molecule, after binding to C1 domain, protrude forming a cap. Bry-1, although is a hydrophilic molecule, which binds strongly to PKC, with a potency similar to that of phorbol ester (a canonical hydrophobic ligand), causing PKC-α, β and δ down-regulation and no PKC-ε and RasGRP3 (RAS guanyl releasing protein 3 (calcium and DAG-regulated)) induction [50,51]. In brief, Bry-1 awakens a fast short activation and self-phosphorylation of PKCs that consecutively induces PKCs membrane
translocation with succeeding PKCs down-regulation. The down-regulation of PKC-δ isozyme shows a distinctive biphasic pattern: at low concentrations—a down-regulation and at higher concentrations—a mechanism of protection [51]. This property contributes in making Bry-1 an attractive drug for pharmaceutical development.

Preclinical studies show that Bry-1 is able to:

(i) enhance spatial learning and long-term memory in rats, mice, rabbits and the nudibranch (Hermissenda) [52,53];
(ii) increase spinophilin (regulatory subunit of protein phosphatase-1 catalytic subunit highly enriched in dendritic spines) and synaptophysin (major synaptic vesicle protein p38), synaptic proteins levels causing synapses structural changes [52];
(iii) exert neuroprotective effects on AD transgenic mice [54];
(iv) improve memory (measured as reduction in latency to escape, after oral Bry-1) in APP/PS1 (mice containing human transgenes for both amyloid precursor protein (APP), bearing the Swedish KM670/671NL (rs63751263, rs63750445) mutation and PSEN1 containing an L166P mutation (rs63750265), both under the control of the Thy1 promoter) transgenic mouse [55];
(v) reduce Aβ levels in monomeric Aβ-treated cells “in vitro” [56];
(vi) reduce Aβ levels in Tg2576 AD mouse (mice overexpressing a mutant form of APP (isoform 695)) and aged rat recovery [57];
(vii) recover neurotrophic activity and synapses loss [57];
(viii) prevent neuronal apoptosis [57];
(ix) inhibit τ phosphorylation by GSK-3β inhibition [57];
(x) enhance synaptogenesis, leading cognitive deficits recovery [57].

Currently, three human trials are ongoing with the aim to exploit the role of Bry-1 in AD (Table 1) [58–60]. Neurotrope, Inc. (OTCQB: NTRP), the company producing Bry-1, announces positive top-line results from a randomized, double-blind, placebo-controlled, single dose Phase IIa clinical trial (ClinicalTrials.gov identifier NCT02221947) evaluating Bry-1 for the treatment of AD showing preliminary safety and tolerability data and no serious adverse events [61]. Moreover, the company (NTRP) has been granted orphan drug designation by the FDA for Bry-1 in the treatment of Fragile X Syndrome (FXS) [62]. FXS is the principle cause of “inherited intellectual disability” including moderate to severe learning disabilities, behavioral disorders, and cognitive impairment, and of autism or autism spectrum disorders. FXS is caused by a partial or a full mutation of the FMR1 gene [63]. Currently, there are no FDA-approved drugs for FXS. Bry-1 is also in preclinical studies in Niemann-Pick type C (NPC) mice with the aim to confirm previous “in vitro” studies suggesting efficacy in correcting NPC cholesterol transport defect [64]. NPC is a rare (the highest incidence 1% in Nova Scotia) devastating genetic disorder in children characterized by progressive neurodegeneration [65]. Although NPC is a really rare autosomal recessive disease, it shows some neuropathological similarities with AD, such as neurofibrillary tangles and deregulated Aβ metabolism. According to Malnar et al., the strongest common denominator is the link to genes involved in cholesterol metabolism [66]. Additional studies on similarities and differences between AD and NPC may support the use of Bry-1 in both diseases. However, overall Bryostatin studies sustain the concept that the paradigm “one-disease-one-drug-one-target” is now “history”.
Table 1. Marine organisms drug derivatives in human clinical trials in Alzheimer’s Disease (AD).

| ClinicalTrials.Gov Identifier | Title of the Trial                                                                 | Study Design/Endpoint Classification | Primary Purpose                                                                                                                                                                                                 | Ref |
|-------------------------------|------------------------------------------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| NCT00606164 Verified: January 2008 by Blanchette Rockefeller Neurosciences Institute. | Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin-1 in Patients With AD. | Randomized Interventional Safety/Efficacy Study Double Blind *                                                                 | Find out single-dose safety. This study is also being done: (1) to determine how effective a single dose of Bry-1 is in the treatment of AD; (2) to find out what happens to Bry-1 once it enters the body by measuring the levels of Bry-1 in blood; (3) to measure PKC-C in the blood. | [58] |
| NCT02221947 Terminated Verified: April 2015 (not specified) | Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin-1 in Patients With AD. | Randomized Safety/Efficacy Study Double Blind*                                                                 | Evaluate the safety and tolerability following a single intravenous dose                                                                                                                                  | [59] |
| NCT02431468 Verified: April 2015 by Neurotrope Bioscience, Inc. | A Study Assessing Bryostatin-1 in the Treatment of Moderately Severe to Severe AD. | Randomized Safety/Efficacy Study Double Blind*                                                                 | To compare different doses for the treatment of moderately severe to severe AD. The study is 28 weeks in duration, including a safety and efficacy 30 days evaluation after the last dose of the study drug. | [60] |
| Homotaurine: (Tramiprosate) C₃H₉NO₃S M.W. 139.17 from a red alga Grateloupia livid | Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate AD. | Randomized, double-blind, placebo-controlled, parallel-group study conducted at 67 study centers across the United States and Canada | Evaluate the long-term safety. Secondary Outcome Measures: To provide additional long-term data on the efficacy of Tramiprosate (3APS). No significant treatment effect | [67,68] |
| – | Homotaurine induces measurable changes of short latency afferent inhibition in a group of MCI individuals. | 10 MCI patients at 100 mg for 4 weeks | SLAI cortical inhibitory circuit changes, no SICI changes, unable to induce changes of the LTP/LTD mechanisms                                                                                                   | [70] |
### Table 1. Cont.

| ClinicalTrials.Gov Identifier | Title of the Trial                                                                 | Study Design/Endpoint Classification | Primary Purpose                                                                 | Ref |
|------------------------------|-----------------------------------------------------------------------------------|--------------------------------------|--------------------------------------------------------------------------------|-----|
| GTS-21: C₁₉H₂₈N₂O₂ M.W. 308.374, anabaseine synthetic derivative from *Nemertines* (ribbon worms). | A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 mg TID, 50 mg TID, 75 mg TID and 150 mg TID) When Administered Daily for 28 Days to Participants With Probable AD. | Randomized Double-Blind | Endpoint Classification: Safety/Efficacy Study Primary Purpose: Treatment The study amperes as completed, however no results are present | [72, 73] |
| NCT00414622 Last Updated: April 18, 2007 | – A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of AD: the DARAD trial. | DARAD study: multicenter, blinded, randomized, placebo-controlled factorial doxycycline and rifampin | Neither rifampin nor doxycycline provided any benefit to patients with AD. | [74] |
| – | A randomized, controlled trial of doxycycline and rifampin for patients with AD. | Randomized, triple-blind, controlled trial. | Possible therapeutic role in patients with mild to moderate AD | [75] |

---

Rifamycins: C₄₃H₅₇O₁₂N₄ M.W. 822.036 previously known to be produced only by soil actinobacteria *Amycolatopsis* is produced by marine bacteria—*Salinispora* isolated from the marine sponge *Pseudoceratinaclavata*.

* Subject, Caregiver, Investigator, Outcomes Assessor; LTD: prolonged long-term depression; LTP: long-term potentiation (synaptic plasticity); SICI: intracortical inhibition; SLAI: short latency afferent inhibition, a neurophysiological measure of central cholinergic transmission.
2.2. Drugs in Ongoing Clinical Trials

At the moment, several marine natural products and their derivatives (Figure 1) are under evaluation as novel drugs for the treatment of neurological disorders, including AD (see Table 1).

Homotaurine (tramiprosate, a small aminosulfonate compound, Figure 1) obtained by red marine algae was evaluated in phase III clinical trials in mild-to-moderate AD [67], showing no enough clinical efficacy [68]. However, looking at secondary endpoints of the study such as lower decline in memory function and reduction in global cognitive decline in APOEε4 allele carriers subgroups of patients, some disease-modifying effects are reported [69]. Homotaurine in preclinical models shows neuroprotective effect inhibiting Aβ activity and by γ-aminobutyric acid type A receptor affinity [69]. A small study was conducted on 10 MCI patients with the aim to study the effects of homotaurine on motor cortical excitability (Table 1) [70]. Homotaurine induced changes of short latency afferent inhibition (SLAI) SLAI measures the impairment of central cholinergic functions “in vivo” and consists “in the inhibition of the Motor Evoked Potentials (MEPs) by afferent sensory impulses” [71]. It has been suggested that Homotaurine-dependent effects, related to changes of cortical GABA transmission, may ameliorate the cholinergic transmission [70].

Homotaurine protects neurons both “in vitro” (NGF-differentiated PC12 cells and primary cortical neurons) and “in vivo” (in rats subjected to the intraluminal filament model of MCAO: Middle cerebral artery occlusion) against ischemic stroke, through disruption of the interaction between PSD95 and nNOS and inhibition of nNOS translocation [76]. The scaffolding protein postsynaptic density-95 (PSD95) binds to both NMDARs and nNOS at excitatory synapses.

Homotaurine was evaluated in a single blind, randomized, controlled study (24 patients versus 13 controls) to evaluate safety and efficacy in Parkinson’s disease (PD) patients with cognitive impairment. After six months of treatment no difference was reported between groups and no adverse effect. A beneficial effect of Homotaurine was observed only on excessive sleepiness in patients with PD [77].

GTS-21 (Figure 1) a synthetic derivative of anabaseine is in phase II for participants with probable diagnosis of AD [72] but with discouraging results. GTS-21 is a partial agonist of α4β2- and α7-nAChR subtypes, able to significantly activate α7 [73].

Rifampicins (Figure 1), a class of broad-spectrum antibiotics, previously known to be produced only by soil actinobacteria Amycolatopsis is also produced by the marine bacteria Salinispora isolated from the marine sponge Pseudoceratinaclavata [78]. It has been proposed that Rifampicin may exert a neuroprotective effects through both scavenging free radicals mechanisms and inhibition of Aβ fibrillar formation (reviewed in [79]). The decrease of intracellular accumulation of Aβ1–40 seams associated with Pgp up-regulation Rifampicin-mediated (reviewed in [79]). On the basis of these preclinical evidences Rifampicin, in association with doxycycline, was evaluated on AD patients (Table 1), however, with discouraging results [74,75].

2.3. Drugs in Preclinical Evaluations

Actually, FDA/EMA-approved drugs work on cholinergic (donepezil, rivastigmine, galantamine) or glutamatergic (memantine) hypothesis. Randomized clinical trials based on the amyloid cascade hypothesis completely failed. Consequently, it was a leitmotiv for a search for new promising targets and marine compounds discussed in all the Review. Among marine derivative drugs, currently under study, we selected only those compounds able to interfere to that molecular processes possible involved in causatives of AD. Specifically, we describe drugs showing activity in (i) τ inhibition such as Anhydroexfoliamycin, Gracilins, 13-desmethyl spiriloide-C and Dictyostatin; (ii) CDC2-like kinase inhibition, such as Leucettamine B, and KH-CB19; (iii) Aβ aggregation inhibition, such as peptides HTP-1 and Gymnodimin. Table 2 and Figure 1 show drugs currently in preclinical development in AD mouse-model system or in cell cultures [80–86]. Compounds, such as AChEI assayed only in “in vitro” enzymatic assay, although, potentially interesting, are not discussed.
Figure 1. Cont.
Figure 1. Chemical structures. Chemical structures were drawn using ACD/ChemSketch®.
Table 2. Marine organisms drug derivatives in pre-clinical trials in AD.

| Drug                           | Source                        | Target                                  | Cellular/Animal Model | Effect                                                | Ref  |
|-------------------------------|-------------------------------|-----------------------------------------|-----------------------|-------------------------------------------------------|------|
| Anhydroexfoliamycin:          | *Streptomyces exfoliatus*     | GSK3β mediated by the JNK pathway       | 3xTg-AD mice          | GSK3β inhibition τ, phosphorylation reduction         | [78] |
| C_{22}H_{24}O_{8} M.W. 416.421| from marine soil             |                                         |                       |                                                       |      |
| Gracilins: C_{23}H_{34}O_{5}  | *Spongionella* sp.            | Mitochondrial targeting through the induction of Nrf2 translocation. BACE1 and ERK inhibition, τ hyperphosphorylation reduction. | 3xTg-AD mice          | After chronic intraperitoneal treatments, a preliminary behavioral test pointed a positive trend on learning and spatial memory of mice treated with these compounds. Moreover, in vivo assays confirmed the previous results. Amyloid-β42 and hyperphosphorylated tau levels were decreased after treatments and the ERK inhibition was also observed. | [79] |
| M.W. 390.513                  |                               |                                         |                       |                                                       |      |
| 13-desmethyl spirolide-C (SPX)| *Alexandriumostenfeldii/ peruvianum dinoflagellates* | Decrease GSK-3β and ERK.                | 3xTg mice cortical neurons | Glutamate-induced neurotoxicity inhibition both in control and 3xTg neurons. | [74] |
| C_{42}H_{61}NO_{7} M.W. 691.944 Spirolides* |                               |                                         |                       |                                                       |      |
| Dictyostatin: C_{32}H_{52}O_{6}| *Spongia* sp. and Caribbean sponge family Corallistidae | MT-stabilizing agent                    | CD1 mice              | MT-stabilization in the brain one week after 5 mg/kg i.p. administration | [75] |
| M.W. 532.751                  |                               |                                         |                       |                                                       |      |
| Leucettamine B:               | *Leucettamicroraphis*         | CLK1, Dyrk1A and Dyrk2 inhibition and CLK3 moderate inhibition. | Human U937 cell membrane |                                                       | [80] |
| C_{12}H_{11}N_{3}O_{3} M.W. 245.234 | Haeckel (Calcarea) sponge    |                                         |                       |                                                       |      |

CDC2-like kinase inhibitors
Table 2. Marine organisms drug derivatives in pre-clinical trials in AD.

| Drug                  | Source                        | Target              | Cellular/Animal Model | Effect                                                                 | Ref |
|-----------------------|-------------------------------|---------------------|-----------------------|----------------------------------------------------------------------|-----|
| KH-CB19:              | Dichothrix baueriana          | CLK1 and Dyrk1A     | Inhibition of human   | Inhibition of human recombinant CLK1 (148 to 484 amino acids) expressed in Escherichia coli BL21. |     |
| C_{15}H_{13}Cl_{2}N_{2}O_{2} M.W. 338.188 dichloroindolylenaminonitrile derived from bauerine C | blue-green alga | potent inhibitor.     | expressed in Escherichia coli BL21.                                 | –   | [80] |
|                      |                               |                     |                       | –                                                                      |     |
| Amyloid-β Aggregation Inhibitors |                               |                     |                       |                                                                       |     |
| Trimaculatus-derived neuroprotective peptides | Hippocampus trimaculatus (seahorse) | –                   | PC12                  | Aβ42-induced neuronal death protection. Bcl-2 up-regulation.          |     |
| HTP-1: Gly-Thr-Glu-Asp-Glu-Leu-Asp-Lys: C_{36}H_{56}O_{18}N_{9} M.W. 902.889 |                     | –                   |                       |                                                                       |     |
| Gymnodimin macrocyclic imine metabolite: | Kareniaselliformis (formerly named Gymnodinium selliformis) (dinoflagellate) | Antagonize human α7-nAChR expressed in Xenopus oocytes | 3xTg mice cortical neurons | Aβ intracellular accumulation, τ hyperphosphorylation reduction, Glutamate-induced neuronal death prevention |     |
| C_{32}H_{45}O_{2}N M.W. 504.691 |                     | 3xTg mice cortical neurons |                       |                                                                       |     |

* Not affect the steady-state levels of neither the M1 and M2 muscarinic nor the α7-nAChR, while it decreased the amplitude of ACh-evoked responses and increased ACh levels in 3xTg neurons.
3. Concluding Remarks

The success stories of Cytarabine (ATC code L01BC01), Trabectedin (ATC code L01CX01), Eribulin (ATC code L01XX41) and Ziconotide (ATC code N02BG08) [33–39] as well as the rich pipeline of clinical, preclinical and tool compounds from marine organisms, especially from microorganisms, (see Tables 1 and 2) make clear that the marine world offers a great reservoir of potential investigational drugs. The specificity of singular marine habitats yields compounds structurally unique. On the other hand, the use of these compounds is limited by their chemical complexity and natural scarcity amounts. The chemical synthesis is the only approach to obtain unlimited quantities, however, the high complexity of certain structures may make synthesis difficult, and, in some cases, impractical. Indeed, in 1990 Corey won the Nobel Prize in Chemistry “for his development of the theory and methodology of organic synthesis” that then allows the synthesis of Ecteinascidin (Trabectedin) [87] originally purified by the tunicate Ecteinascidia turbinata only in very small amounts.

In spite of the observation that a great number of compounds with different interesting pharmacological profile arrive to preclinical studies, the majority of them did not succeed the clinical studies. Indeed, Cummings et al. [88] examining the Clinicaltrials.gov database, a public website that records ongoing clinical trials, for the period time 2002–2012 retrieve 413 AD human trials: 124 Phase I, 206 Phase II, and 83 Phase III. In this decade only three agents reached the FDA/EMA approval. The study of Cummings et al. [88] definitively proved that the development of an effective drug for AD is very difficult and the pipeline is the lowest in comparison with any other therapeutic area [29].

The likelihood to create different effective bioactive products starting by a scaffold obtained by a marine natural product is now possible through technology improvements both in harvesting samples, and in purifying, and characterizing products. Therefore, the ocean resources may be regularly exploited for designing and producing of drug discovery pipeline.

Author Contributions: All authors contributed as the same for the manuscript preparation and design.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. World Alzheimer Report 2015. Available online: http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf (accessed on 3 September 2015).
2. Sachdev, P.S.; Blacker, D.; Blazer, D.G.; Ganguli, M.; Jeste, D.V.; Paulsen, J.S.; Petersen, R.C. Classifying neurocognitive disorders: The DSM-5 approach. Nat. Rev. Neurol. 2014, 10, 634–642. [CrossRef] [PubMed]
3. Van Cauwenberghe, C.; Van Broeckhoven, C.; Sleegers, K. The genetic landscape of Alzheimer disease: Clinical implications and perspectives. Genet. Med. 2015. [CrossRef] [PubMed]
4. Hauser, P.S.; Narayanaswami, V.; Ryan, R.O. Apolipoprotein E: From lipid transport to neurobiology. Prog. Lipid Res. 2011, 50, 62–74. [CrossRef] [PubMed]
5. Kumar, A.; Ekavali, A.S. A review on Alzheimer’s disease pathophysiology and its management: An update. Pharmacol. Rep. 2015, 67, 195–203. [CrossRef] [PubMed]
6. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353–356. [CrossRef] [PubMed]
7. Bartus, R.T. On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 2000, 163, 495–529. [CrossRef] [PubMed]
8. Zádori, D.; Veres, G.; Szalárdy, L.; Klivényi, P.; Toldi, J.; Vécsei, L. Glutamatergicdysfunctioning in Alzheimer’s disease and related therapeutic targets. J. Alzheimers Dis. 2014, 42, 177–187. [CrossRef]
9. Swerdlow, R.H.; Burns, J.M.; Khan, S.M. The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives. Biochim. Biophys. Acta. 2014, 1842, 1219–1231. [CrossRef] [PubMed]
10. Milic, M.; Frustaci, A.; Del Bufalo, A.; Sánchez-Alarcón, J.; Valencia-Quintana, R.; Russo, P.; Bonassi, S. DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutat. Res. 2015, 776, 118–127. [CrossRef] [PubMed]
11. Demetrius, L.A.; Driver, J. Alzheimer’s as a metabolic disease. *Biogerontology* 2013, 14, 641–649. [CrossRef] [PubMed]
12. Medina, M.; Avila, J. New perspectives on the role of tau in Alzheimer’s disease. Implications for therapy. *Biochem. Pharmacol.* 2014, 88, 540–547. [CrossRef] [PubMed]
13. Lucke-Wold, B.P.; Turner, R.C.; Logsdon, A.F.; Simpkins, J.W.; Alkon, D.L.; Smith, K.E.; Chen, Y.W.; Tan, Z.; Huber, J.D.; Rosen, C.L. Common mechanisms of Alzheimer’s disease and ischemic stroke: The role of protein kinase C in the progression of age-related neurodegeneration. *J. Alzheimers Dis.* 2015, 43, 711–724. [CrossRef] [PubMed]
14. Heppner, F.L.; Ransohoff, R.M.; Becher, B. Immune attack: The role of inflammation in Alzheimer disease. *Nat. Rev. Neurosci.* 2015, 16, 358–372. [CrossRef] [PubMed]
15. Ofek, K.; Soreq, H. Cholinergic involvement and manipulation approaches in multiple system disorders. *Chem. Biol. Interact.* 2013, 203, 113–119. [CrossRef] [PubMed]
16. Tarasoff-Conway, J.M.; Carare, R.O.; Osorio, R.S.; Glodzik, L.; Butler, T.; Fieremans, E.; Axel, L.; Rusinek, H.; Nicholson, C.; Zlokovic, B.V.; et al. Clearance systems in the brain-implications for Alzheimer disease. *Nat. Rev. Neurol.* 2015, 11, 457–470. [CrossRef] [PubMed]
17. Xu, W.; Yu, J.T.; Tan, M.S.; Tan, L. Cognitive reserve and Alzheimer’s disease. *Mol. Neurobiol.* 2015, 51, 187–208. [CrossRef] [PubMed]
18. Stam, C.J. Modern network science of neurological disorders. *Nat. Rev. Neurosci.* 2014, 15, 683–695. [CrossRef] [PubMed]
19. Vecchio, F.; Miraglia, F.; Curcio, G.; Altavilla, R.; Scrascia, F.; Giambattistelli, F.; Quattrocchi, C.C.; Bramanti, P.; Vernieri, F.; Rossini, P.M. Cortical brain connectivity evaluated by graph theory in dementia: A correlation study between functional and structural data. *J. Alzheimers Dis.* 2015, 45, 745–756. [CrossRef] [PubMed]
20. Zanzoni, A. A Computational Network biology approach to uncover novel genes related to Alzheimer’s disease. *Methods Mol. Biol.* 2016, 1303, 435–446. [CrossRef] [PubMed]
21. Herrup, K. The case for rejecting the amyloid cascade hypothesis. *Nat. Neurosci.* 2015, 18, 794–799. [CrossRef] [PubMed]
22. Russo, P.; Kisialiou, A.; Moroni, R.; Prinzi, G.; Fini, M. Effect of genetic polymorphisms (SNPs) in CHRNA7 gene on response to acetylcholinesterase Inhibitors (AChEI) in patients with Alzheimer’s disease. *Curr. Drug Targets* 2015, in press. [CrossRef]
23. Parri, H.R.; Hernandez, C.M.; Dineley, K.T. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer’s disease. *Biochem. Pharmacol.* 2011, 82, 931–942. [CrossRef] [PubMed]
24. Talantova, M.; Sanz-Blasco, S.; Zhang, X.; Xia, P.; Akhtar, M.W.; Okamoto, S.; Dziewczapolski, G.; Nakamura, T.; Cao, G.; Pratt, A.E.; et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. USA.* 2013, 110, E2518–E2527. [CrossRef] [PubMed]
25. Colović, M.B.; Krstić, D.Z.; Lazarević-Paštš, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. *Curr. Neuropharmacol.* 2013, 11, 315–335. [CrossRef] [PubMed]
26. Langa, K.M.; Levine, D.A. The diagnosis and management of mild cognitive impairment: A clinical review. *JAMA* 2014, 312, 2551–2561. [CrossRef] [PubMed]
27. Rolinski, M.; Fox, C.; Maidment, I.; McShane, R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. *Cochrane Database Syst. Rev.* 2012, 3, CD006504. [CrossRef] [PubMed]
28. Qizilbash, N.; Birks, J.; Lopez-Arrieta, J.; Lewington, S.; Szeto, S. WITHDRAWN: Tacrine for Alzheimer’s disease. *Cochrane Database Syst. Rev.* 2007, 18, CD000202. [CrossRef] [PubMed]
29. FDA Approved Drugs. Available online: http://www.centerwatch.com/drug-information/fda-approved-drugs/year/2015/2014/2013 (accessed on 16 September 2015).
30. First WHO Ministerial Conference on Global Action Against Dementia. Available online: http://www.who.int/mediacentre/events/meetings/2015/global-action-against-dementia/en/ (accessed on 16 September 2015).
31. Koslow, T. *The Silent Deep: The Discovery, Ecology and Conservation of the Deep Sea*; University Chicago Press: Chicago, IL, USA, 2007; pp. 1–288.
32. Russo, P.; Del Bufalo, A.; Fini, A. Deep sea as a source of novel-anticancer drugs: Update on discovery and preclinical/clinical evaluation in a systems medicine perspective. *EXCLI J.* 2015, 14, 228–236. [CrossRef] [PubMed]

33. Catassi, A.; Cesario, A.; Arzani, D.; Menichini, P.; Alama, A.; Bruzzo, C.; Imperatori, A.; Rotolo, N.; Grano, P.; Russo, P. Characterization of apoptosis induced by marine natural products in non small cell lung cancer A549 cells. *Cell Mol. Life Sci.* 2006, 63, 2377–2386. [CrossRef] [PubMed]

34. Russo, P.; Nastrucci, C.; Cesario, A. From the sea to anticancer therapy. *Curr. Med. Chem.* 2011, 18, 3551–3562. [CrossRef] [PubMed]

35. Nastrucci, C.; Cesario, A.; Russo, P. Anticancer drug discovery from the marine environment. *Recent Pat. Anticancer Drug Discov.* 2012, 7, 218–232. [CrossRef] [PubMed]

36. Russo, P.; Cesario, A. New anticancer drugs from marine cyanobacteria. *Curr. Drug Targets* 2012, 13, 1048–1053. [CrossRef] [PubMed]

37. Russo, P.; Del Bufalo, A. Conopeptides in addiction disorders treatment. *Int. J. Adv. Res. Chem. Sci. IJARCS* 2015, in press.

38. Martins, A.; Vieira, H.; Gaspar, H.; Santos, S. Marketed marine natural products in the pharmaceutical and cosmeceutical industries: Tips for success. *Mar. Drugs* 2014, 12, 1066–1101. [CrossRef] [PubMed]

39. Gerwick, W.H.; Moore, B.S. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. *Chem. Biol.* 2012, 19, 85–98. [CrossRef] [PubMed]

40. Kollár, P.; Rajchard, J.; Balounová, Z.; Pazourek, J. Marine natural products: Bryostatins in preclinical and clinical studies. *Pharm Biol.* 2014, 52, 237–242. [CrossRef] [PubMed]

41. Ruan, B.F.; Zhu, H.L. The chemistry and biology of the bryostatins: Potential PKC inhibitors in clinical development. *Curr. Med. Chem.* 2012, 19, 2652–2664. [CrossRef]

42. Pettit, G.R.; Cherry Herald, L.; Doubek, D.L.; Herald, D.L.; Arnold, E.; Clardy, J. Total synthesis of bryostatin 1. *J. Am. Chem. Soc.* 1982, 104, 6846–6848. [CrossRef]

43. Keck, G.E.; Poudel, Y.B.; Cummins, T.J.; Rudra, A.; Covel, J.A. Total synthesis of bryostatin 1. *J. Am. Chem. Soc.* 2011, 133, 744–747. [CrossRef] [PubMed]

44. Manaviazar, S.; Hale, K.J. Total synthesis of bryostatin 1: A short route. *Angew. Chem. Int. Ed. Engl.* 2011, 50, 8786–8789. [CrossRef] [PubMed]

45. Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer. ClinicalTrials.gov Identifier: NCT00006389. Available online: https://clinicaltrials.gov/ct2/show/NCT00006389 (accessed on 16 September 2015).

46. Laird, G.M.; Bullen, C.K.; Rosenbloom, D.I.; Martin, A.R.; Hill, A.L.; Durand, C.M.; Siliciano, J.D.; Siliciano, R.F. *Ex vivo* analysis identifies effective HIV-1 latency-reversing drug combinations. *J. Clin. Investig.* 2015, 125, 1901–1912. [CrossRef] [PubMed]

47. Díaz, L.; Martínez-Bonet, M.; Sánchez, J.; Fernández-Pineda, A.; Jiménez, J.L.; Muñoz, E.; Moreno, S.; Álvarez, S.; Muñoz-Fernández, M.A. Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-kB-dependent mechanism. *Sci. Rep.* 2015, 5, 12442. [CrossRef] [PubMed]

48. Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment (BRYOLAT). ClinicalTrials.gov Identifier: NCT02269605. Available online: https://clinicaltrials.gov/ct2/show/NCT02269605 (accessed on 16 September 2015).

49. Kazanietz, M.G. Novel “nonkinase” phorbol ester receptors: The C1 domain connection. *Mol. Pharmacol.* 2002, 61, 759–767. [CrossRef] [PubMed]

50. Mochly-Rosen, D.; Das, K.; Grimes, K.V. Protein kinase C, an elusive therapeutic target? *Nat. Rev. Drug Discov.* 2012, 11, 937–957. [CrossRef] [PubMed]

51. Keck, G.E.; Poudel, Y.B.; Rudra, A.; Stephens, J.C.; Kedei, N.; Lewin, N.E.; Blumberg, P.M. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity. *Bioorganic Med. Chem. Lett.* 2012, 22, 4084–4088. [CrossRef] [PubMed]

52. Hongpaisan, J.; Alkon, D.L. A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. *Proc. Natl. Acad. Sci. USA* 2007, 104, 19571–19576. [CrossRef] [PubMed]

53. Xu, C.; Liu, Q.Y.; Alkon, D.L. PKC activators enhance GABAergic neurotransmission and paired-pulse facilitation in hippocampal CA1 pyramidal neurons. *Neuroscience* 2014, 268, 75–86. [CrossRef] [PubMed]
54. Etcheberrigaray, R.; Tan, M.; Dewachter, I.; Kuipéri, C.; van der Auwera, I.; Wera, S.; Qiao, L.; Bank, B.; Nelson, T.J.; Kozikowski, A.P.; et al. Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice. Proc. Natl. Acad. Sci. USA. 2004, 101, 11141–11146. [CrossRef] [PubMed]

55. Schrott, L.M.; Jackson, K.; Yi, P.; Dietz, F.; Johnson, G.S.; Basting, T.F.; Purdum, G.; Tyler, T.; Rios, J.D.; Castor, T.P.; et al. Acute oral Bryostatin-1 administration improves learning deficits in the APP/PS1 transgenic mouse model of Alzheimer’s disease. Curr. Alzheimer Res. 2015, 12, 22–31. [CrossRef] [PubMed]

56. Lim, C.S.; Alkon, D.L. PKCε promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced Aβ degradation in brain neurons. PLoS ONE 2014, 9, e97756. [CrossRef] [PubMed]

57. Hongpaisan, J.; Sun, M.K.; Alkon, D.L. PKCε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J. Neurosci. 2011, 31, 630–643. [CrossRef] [PubMed]

58. Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer’s Disease. Available online: https://www.clinicaltrials.gov/ct2/show/NCT00606164 (accessed on 16 September 2015).

59. Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer’s Disease. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02221947 (accessed on 16 September 2015).

60. A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease. Available online: https://www.clinicaltrials.gov/ct2/show/NCT02431468 (accessed on 16 September 2015).

61. Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer’s Disease. Available online: http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/Bryostatin-1.html (accessed on 16 September 2015).

62. Search Orphan Drug Designations and Approvals. Available online: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (accessed on 16 September 2015).

63. Devitt, N.M.; Gallagher, L.; Reilly, R.B. Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS): Two Overlapping Disorders Reviewed through Electroencephalography—What Can be Interpreted from the Available Information? Brain Sci. 2015, 5, 92–117. [CrossRef] [PubMed]

64. Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease. Available online: http://www.prnewswire.com/news-releases/neurotrope-to-conduct-study-on-niemann-pick-type-c-a-devastating-rare-pediatric-disease-300104024.html (accessed on 16 September 2015).

65. Brady, R.O.; Filling-Katz, M.R.; Barton, N.W.; Pentchev, P.G. Niemann-Pick disease types C and D. Neurol. Clin. 1989, 7, 75–88. [PubMed]

66. Malnar, M.; Hecimovic, S.; Mattsson, N.; Zetterberg, H. Bidirectional links between Alzheimer’s disease and Niemann-Pick type C disease. Neurobiol. Dis. 2014, 72, 37–47. [CrossRef] [PubMed]

67. Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer’s Disease. Available online: https://clinicaltrials.gov/ct2/show/study/NCT00314912 (accessed on 16 September 2015).

68. Aisen, P.S.; Gauthier, S.; Ferris, S.H.; Saumier, D.; Haine, D.; Garceau, D.; Duong, A.; Suhy, J.; Oh, J.; Lau, W.C.; et al. Tramiprosate in mild-to-moderate Alzheimer’s disease—a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 2011, 7, 102–111. [CrossRef] [PubMed]

69. Caltagirone, C.; Ferrannini, L.; Marchionni, N.; Nappi, G.; Scapagnini, G.; Trabucchi, M. The potential protective effect of tramiprosate (homotaurine) against Alzheimer’s disease: A review. Aging Clin. Exp. Res. 2012, 24, 580–587. [CrossRef] [PubMed]

70. Mantorana, A.; di Lorenzo, F.; Manenti, G.; Semprini, R.; Koch, G. Homotaurine induces measurable changes of short latency afferent inhibition in a group of mild cognitive impairment individuals. Front. Aging Neurosci. 2014, 6, 254. [CrossRef] [PubMed]

71. Tokimura, H.; di Lazzaro, V.; Tokimura, Y.; Oliviero, A.; Profic, P.; Insola, A.; Mazzone, P.; Tonali, P.; Rothwell, J.C. Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J. Physiol. 2000, 523, 503–513. [CrossRef] [PubMed]

72. GTS21-201 for Alzheimer Disease: GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease. Available online: https://clinicaltrials.gov/ct2/show/study/NCT00414622 (accessed on 16 September 2015).
73. Russo, P.; Del Bufalo, A.; Frustaci, A.; Fini, M.; Cesario, A. Beyond acetylcholinesterase inhibitors for treating Alzheimer’s disease: α7-nAChR agonists in human clinical trials. Curr. Pharm. Des. 2014, 20, 6014–6021. [CrossRef] [PubMed]

74. Molloy, D.W.; Standish, T.I.; Zhou, Q.; Guyatt, G. DARAD Study Group. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer’s disease: The DARAD trial. Int. J. Geriatr. Psychiatry 2013, 28, 463–470. [CrossRef] [PubMed]

75. Loeb, M.B.; Molloy, D.W.; Smieja, M.; Standish, T.; Goldsmith, C.H.; Mahony, J.; Smith, S.; Borrie, M.; Decoteau, E.; Davidson, W.; et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J. Am. Geriatr. Soc. 2004, 52, 381–387. [CrossRef] [PubMed]

76. Wu, S.; Yue, Y.; Tian, H.; Tao, L.; Wang, Y.; Xiang, J.; Wang, S.; Ding, H. Tramiprosate protects neurons against ischemic stroke by disrupting the interaction between PSD95 and nNOS. Neuropharmacology 2014, 83, 107–117. [CrossRef]

77. Ricciardi, L.; de Nigris, F.; Specchia, A.; Fasano, A. Homotaurine in Parkinson’s disease. Neurol. Sci. 2015, 36, 1581–1587. [CrossRef] [PubMed]

78. Kim, T.K.; Hewavitharana, A.K.; Shaw, P.N.; Fuerst, J.A. Discovery of a new source of rifamycin antibiotics in marine sponge actinobacteria by phylogenetic prediction. Appl. Environ. Microbiol. 2006, 72, 2118–2125. [CrossRef] [PubMed]

79. Yulug, B.; Hanoglu, L.; Kilic, E.; Schabitz, W.R. RIFAMPICIN: An antibiotic with brain protective function. Brain Res. Bull. 2014, 107, 37–42. [CrossRef] [PubMed]

80. Leirós, M.; Alonso, E.; Rateb, M.E.; Ebel, R.; Jaspars, M.; Alfonso, A.; Botana, L.M. The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer’s disease in vitro and in vivo. Neuroscience 2015, 305, 26–35. [CrossRef] [PubMed]

81. Leirós, M.; Alonso, E.; Rateb, M.E.; Houssen, W.E.; Ebel, R.; Jaspars, M.; Alfonso, A.; Botana, L.M. Gracilins: Spongionella-derived promising compounds for Alzheimer disease. Neuropharmacology 2015, 93, 285–293. [CrossRef] [PubMed]

82. Alonso, E.; Vale, C.; Vieytes, M.R.; Laferla, F.M.; Giménez-Llort; Botana, L.M. 13-Desmethyl spirolide-C is neuroprotective and reduces intracellular Aβ and hyperphosphorylated tau in vitro. Neurochem. Int. 2011, 59, 1056–1065. [CrossRef] [PubMed]

83. Jain, P.; Karthikeyan, C.; Moorthy, N.S.; Waiker, D.K.; Jain, A.K.; Trivedi, P. Human CDC2-like kinase 1 (CLK1): A novel target for Alzheimer’s disease. Curr. Drug Targets 2014, 15, 539–550. [CrossRef] [PubMed]

84. Pangestuti, R.; Ryu, B.; Himaya, S.; Kim, S.K. Optimization of hydrolysis conditions, isolation, and identification of neuroprotective peptides derived from seahorse Hippocampus trimaculatus. Amino Acids 2013, 45, 369–381. [CrossRef] [PubMed]

85. Alonso, E.; Vale, C.; Vieytes, M.R.; Laferla, F.M.; Giménez-Llort; Botana, L.M. The cholinergic antagonist gymnodi- mine improves Aβ and tau neuropathology in an in vitro model of Alzheimer disease. Cell Physiol. Biochem. 2001, 27, 783–794. [CrossRef] [PubMed]

86. Brunden, K.R.; Gardner, N.M.; James, M.J.; Yao, Y.; Trojanowski, J.Q.; Lee, V.M.; Paterson, I.; Ballatore, C.; Smith, A.B., 3rd. MT-stabilizer, dictyostatin, exhibits prolonged brain retention and activity: Potential therapeutic implications. ACS Med. Chem. Lett. 2013, 4, 886–889. [CrossRef] [PubMed]

87. The Nobel Prize in Chemistry 1990. Available online: http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1990/ (accessed on 24 December 2015).

88. Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res. Ther. 2014, 6, 37. [CrossRef] [PubMed]